Editas and Allergan Make Gene-Editing History With First Treatment of Blindness DrugThe Motley Fool • 03/04/20
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10GlobeNewsWire • 03/04/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat CancerGlobeNewsWire • 01/13/20
Editas Medicine Strengthens Executive Leadership Team to Support Long-term GrowthGlobeNewsWire • 01/09/20
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Goes To PrisonInvestors Business Daily • 12/30/19
Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should KnowZacks Investment Research • 12/24/19
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-ThalassemiaGlobeNewsWire • 12/09/19
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove ValuableThe Motley Fool • 12/05/19